Abstract: An exercise mat comprising a base layer, a top layer formed of an absorbent material for absorbing sweat, and a barrier layer bonded between the top and base layers for preventing sweat from seeping from the top layer into the base layer in use. Preferably, the barrier layer is formed of a breathable material.

Abstract: Gene expression data provides a basis for more accurate identification and diagnosis of lymphoproliferative disorders. In addition, gene expression data can be used to develop more accurate predictors of survival. The present invention discloses methods for identifying, diagnosing, and predicting survival in a lymphoma or lymphoproliferative disorder on the basis of gene expression patterns. The invention discloses a novel microarray, the Lymph Dx microarray, for obtaining gene expression data from a lymphoma sample. The invention also discloses a variety of methods for utilizing lymphoma gene expression data to determine the identity of a particular lymphoma and to predict survival in a subject diagnosed with a particular lymphoma. This information will be useful in developing the therapeutic approach to be used with a particular subject.

Abstract: An exercise mat comprising a base layer, a top layer formed of an absorbent material for absorbing sweat, and a barrier layer bonded between the top and base layers for preventing sweat from seeping from the top layer into the base layer in use. Preferably, the barrier layer is formed of a breathable material.

Abstract: Gene expression data provides a basis for more accurate identification and diagnosis of lymphoproliferative disorders. In addition, gene expression data can be used to develop more accurate predictors of survival. The present invention discloses methods for identifying, diagnosing, and predicting survival in a lymphoma or lymphoproliferative disorder on the basis of gene expression patterns. The invention discloses a novel microarray, the Lymph Dx microarray, for obtaining gene expression data from a lymphoma sample. The invention also discloses a variety of methods for utilizing lymphoma gene expression data to determine the identity of a particular lymphoma and to predict survival in a subject diagnosed with a particular lymphoma. This information will be useful in developing the therapeutic approach to be used with a particular subject.

Abstract: A secure secrets proxy is instantiated in a first computing environment and includes secure secrets proxy authentication data for identifying itself to a secrets distribution management system in a second computing environment as a trusted virtual asset to receive and cache secrets data in a secure secrets cache outside the second computing environment. A virtual asset requests one or more secrets, triggering a process to authenticate the requesting virtual asset, gathering authorized secrets data representing secrets the virtual asset is allowed to have. The secure secrets proxy is provided data representing the requested secrets and stores that secrets data in the secure secrets cache of the proxy.

Abstract: A secure secrets proxy is instantiated in a first computing environment and includes secure secrets proxy authentication data for identifying itself to a secrets distribution management system in a second computing environment as a trusted virtual asset to receive and cache secrets data in a secure secrets cache outside the second computing environment. A virtual asset requests one or more secrets, triggering a process to authenticate the requesting virtual asset, gathering authorized secrets data representing secrets the virtual asset is allowed to have. The secure secrets proxy is provided data representing the requested secrets and stores that secrets data in the secure secrets cache of the proxy.

Abstract: Secrets data representing one or more secrets required to access associated resources is provided along with secrets distribution policy data representing one or more secrets distribution factors used to control the distribution of the secrets. When a requesting virtual asset submits secrets request data, virtual asset profile data associated with the requesting virtual asset is obtained. The requesting virtual asset profile data is then analyzed using at least one of the secrets distribution factors to authenticate the requesting virtual asset. The requesting virtual asset profile data is then analyzed using one or more of secrets distribution factors to determine what secrets the requesting virtual asset legitimately needs. Authorized secrets data for the requesting virtual asset representing one or more authorized secrets is then generated. The requesting virtual asset is then provided access to the authorized secrets data.

Abstract: Secrets data representing one or more secrets required to access associated resources is provided along with secrets distribution policy data representing one or more secrets distribution factors used to control the distribution of the secrets. When a requesting virtual asset submits secrets request data, virtual asset profile data associated with the requesting virtual asset is obtained. The requesting virtual asset profile data is then analyzed using at least one of the secrets distribution factors to authenticate the requesting virtual asset. The requesting virtual asset profile data is then analyzed using one or more of secrets distribution factors to determine what secrets the requesting virtual asset legitimately needs. Authorized secrets data for the requesting virtual asset representing one or more authorized secrets is then generated. The requesting virtual asset is then provided access to the authorized secrets data.

Abstract: Gene expression data provides a basis for more accurate identification and diagnosis of lymphoproliferative disorders. In addition, gene expression data can be used to develop more accurate predictors of survival. The present invention discloses methods for identifying, diagnosing, and predicting survival in a lymphoma or lymphoproliferative disorder on the basis of gene expression patterns. The invention discloses a novel microarray, the Lymph Dx microarray, for obtaining gene expression data from a lymphoma sample. The invention also discloses a variety of methods for utilizing lymphoma gene expression data to determine the identity of a particular lymphoma and to predict survival in a subject diagnosed with a particular lymphoma. This information will be useful in developing the therapeutic approach to be used with a particular subject.

Abstract: Gene expression data provides a basis for more accurate identification and diagnosis of lymphoproliferative disorders. In addition, gene expression data can be used to develop more accurate predictors of survival. The present invention discloses methods for identifying, diagnosing, and predicting survival in a lymphoma or lymphoproliferative disorder on the basis of gene expression patterns. The invention discloses a novel microarray, the Lymph Dx microarray, for obtaining gene expression data from a lymphoma sample. The invention also discloses a variety of methods for utilizing lymphoma gene expression data to determine the identity of a particular lymphoma and to predict survival in a subject diagnosed with a particular lymphoma. This information will be useful in developing the therapeutic approach to be used with a particular subject.

Abstract: Gene expression data provides a basis for more accurate identification and diagnosis of lymphoproliferative disorders. In addition, gene expression data can be used to develop more accurate predictors of survival. The present invention discloses methods for identifying, diagnosing, and predicting survival in a lymphoma or lymphoproliferative disorder on the basis of gene expression patterns. The invention discloses a novel microarray, the Lymph Dx microarray, for obtaining gene expression data from a lymphoma sample. The invention also discloses a variety of methods for utilizing lymphoma gene expression data to determine the identity of a particular lymphoma and to predict survival in a subject diagnosed with a particular lymphoma. This information will be useful in developing the therapeutic approach to be used with a particular subject.